老年AML治疗具有挑战性。对于≥70岁的老年患者，缺乏基于证据的建议，而这一人群在临床试验中的代表性较低。随着最近几年出现了新的治疗选择，迫切需要为这些患者提供建议。因此，国际老年肿瘤学学会（SIOG）组织了一个工作组，以评估70岁以上患者的治疗和预后的专门证据。专家小组选取了六个问题，包括（1）基线评估，（2）一线治疗，（3）缓解后治疗，（4）复发治疗，（5）靶向治疗和（6）患者自报告结果/功能和增强治疗耐受性。通过提取当前文献中的信息，综合系统综述/荟萃分析、决策模型、针对这些患者的个别试验和亚组数据的证据。根据全体专家共识，采用GRADE方法生成了相关建议。我们坚定地建议并希望对≥70岁的患者进行直接证据的生成，

Acute myeloid leukemia (AML) treatment is challenging in older patients. There is a lack of evidence-based recommendations for older patients ≥70, a group largely underrepresented in clinical trials. With new treatment options being available in recent years, recommendations are needed for these patients. As such the International Society of Geriatric Oncology (SIOG) assembled a task force to review the evidence specific to treatment and outcomes in this population of patients ≥70 years. Six questions were selected by the expert panel in domains of (1) baseline assessment, (2) frontline therapy, (3) post-remission therapy, (4) treatment for relapse, (5) targeted therapies, and (6) patient reported outcome/function and enhancing treatment tolerance. Information from current literature was extracted, combining evidence from systematic reviews/meta-analyses, decision models, individual trials targeting these patients, and subgroup data. Accordingly, recommendations were generated using a GRADE approach upon reviewing current evidence by consensus of the whole panel. It is our firm recommendation and hope that direct evidence should be generated for patients aged ≥70 as a distinct group in high need of improvement of their survival outcomes. Such studies should integrate information from a geriatric assessment to optimize external validity and outcomes.Copyright © 2023. Published by Elsevier Ltd.